Related references
Note: Only part of the references are listed.Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
Juris J. Meier et al.
DIABETES CARE (2015)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY - CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN-2015
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2015)
Approaches to Glycemic Treatment
[Anonymous]
DIABETES CARE (2015)
Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
Denis Raccah et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2014)
Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
Chang Yu Pan et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2014)
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
G. B. Bolli et al.
DIABETIC MEDICINE (2014)
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
Julio Rosenstock et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Bo Ahren et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
M. Pinget et al.
DIABETES OBESITY & METABOLISM (2013)
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza et al.
DIABETES OBESITY & METABOLISM (2013)
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Andreas B. Petersen et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2013)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Association of Pancreatitis with Glucagon-Like Peptide-I Agonist Use
Sarah L. Anderson et al.
ANNALS OF PHARMACOTHERAPY (2010)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich Werner et al.
REGULATORY PEPTIDES (2010)
Glucagon-like peptide-1, glucose homeostasis and diabetes
Jens J. Holst et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
Share Paper
